申请人:AstraZeneca AB
公开号:US06596711B1
公开(公告)日:2003-07-22
Novel compounds of formula I, with the exception of
i) the racemate of (3-amino-2-hydroxypropyl)methylphosphinic acid;
ii) (S)-(3-amino-2-hydroxypropyl)methylphosphinic acid;
iii) (R)-(3-amino-2-hydroxypropyl)methylphosphinic acid;
iv) (3-amino-2-hydroxypropyl)difluoromethylphosphinic acid; and
v) (3-amino-2-oxopropyl)methylphosphinic acid,
having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.
化合物I的新型化合物,除了i) (3-氨基-2-羟基丙基)甲基膦酸的外消旋体;ii) (S)-(3-氨基-2-羟基丙基)甲基膦酸;iii) (R)-(3-氨基-2-羟基丙基)甲基膦酸;iv) (3-氨基-2-羟基丙基)二氟甲基膦酸;和v) (3-氨基-2-氧代丙基)甲基膦酸,具有对一个或多个GABAB受体的亲和力,其药学上可接受的盐、溶剂化物和立体异构体,以及其制备过程,含有该治疗活性化合物的制药组合物以及在治疗中使用该活性化合物的用途。